Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

Almirall

The Top Pharma List rankings are compiled from GlobalData's pharmaceutical revenue figures, which are based on prescription medicine sales, including generics drugs. They have been compiled below into an infographic of Almirall's 2013 sales performance.

Red Door promotes Matt Lowe and Katy Pogson

Red Door promotes Matt Lowe and Katy Pogson Aldous joined Red Door in 2011 from Red Health as a senior account manager and currently leads accounts for Sanofi, MSD, Baxter, Almirall and Astellas.

EMA backs 15 new medicines for use in EU

EMA backs 15 new medicines for use in EU AstraZeneca and Almirall. There was good news for AstraZeneca (AZ), which received positive opinions for two of its medicines. ... Aclidinium / formoterol fumarate, which is set to be marketed as Brimica Genuair or Duaklir Genuair depending on the country

The M&A trend in pharma

The M&A trend in pharma It is also driving acquisitions that complement the buyer's existing core products, as evidenced by AstraZeneca's $1.2bn acquisition of Almirall's respiratory division and the deal between GSK

Novartis' Ultibro tops Seretide in comparative COPD trial

Novartis' Ultibro tops Seretide in comparative COPD trial With Seretide already succumbing to generic competition and other entrants from AstraZeneca and Forest Laboratories/Almirall also coming through the pipeline, the market is expected to fragment with the new generation

Deal Watch table for July 2014

Deal Watch table for July 2014 2, 700. Almirall/ AstraZeneca. Asset acquisition. Respiratory business including various respiratory assets and device capabilities.

[ Previous 5 results ] 5 6 7 8 9 10 11 12 13 14 [ Next 5 results ]

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
Hanover Communications

Healthcare is evolving rapidly. To stand out from the crowd requires a potent combination of rich insight, innovative ideas and...

Latest intelligence

Report: Reinventing product and portfolio value for the biopharmaceutical industry
Gain practical advice on determining and communicating product and portfolio value, including why, in fast-paced and evolving markets, you need to consider the evidence requirements of a growing network of...
Neil Thompson
How AI is finally helping rare diseases gain more than just attention
By Neil Thompson...
Is communication failing us?
Compelling people to care in a world oversaturated with news and information...